Tuesday, July 21, 2026
🇺🇸 FDA

pharma · Asthma · Multiple Sclerosis · TEVA

Teva Pharma

Teva Pharma GmbH

Teva Pharma patent portfolio — 185 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
10 Dornierstr., Ulm, Donau, 89079, DE, TEL AVIV HQ
126 Employees
Public company Type
TEVA · NYSE Ticker
Company details
Status
Public
HQ
10 Dornierstr., Ulm, Donau, 89079, DE, TEL AVIV
Employees
126
Programs
7
Drugs
407
Patents
185
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Teva Pharma patents

185 pharmaceutical patents indexed for Teva Pharma. 22 expire within 24 months.

Teva Pharma has 185 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 22 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

185 patents

Patent portfolio

Page 1 of 4

  1. US 12310929

    Use of rasagiline for the treatment of restless legs syndrome

    Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11813359

    Sustained release olanzapine formulations

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11135154

    Medroxyprogesterone acetate injectable compositions and methods of use

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10676498

    Processes for the preparation of sofosbuvir and intermediates thereof

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10646443

    Sustained release olanzapine formulations

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10214553

    Solid state forms of sofosbuvir

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10188811

    Nasal spray device

    Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10130621

    Analogs of pridopidine, their preparation and use

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10034866

    Inhalable medicament comprising tiotropium

    Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9814706

    Hydrobromide salt of pridopidine

    Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9796673

    L-tartrate salt of pridopidine

    Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9763993

    Process for manufacturing glatiramer acetate product

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9702007

    Genetic markers predictive of response to glatiramer acetate

    Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9687522

    Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

    Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9662322

    Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

    Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9655969

    Inhalable medicament comprising tiotropium

    Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9625473

    Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

    Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9617596

    Biomarkers predictive for clinical response for glatiramer acetate

    Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9585878

    Treatment of BDNF-related disorders using laquinimod

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9499868

    Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9427578

    Pharmacokinetics of iontophoretic sumatriptan administration

    Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9415008

    Dry powder inhaler

    Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9382200

    Process for the preparation of and crystalline forms of optical enantiomers of modafinil

    Expires Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9375403

    Formulations of 6-mercaptopurine

    Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9340307

    Stable laquinimod preparations

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9308182

    Parenteral formulations of rasagiline

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9272137

    Transdermal methods and systems for the delivery of anti-migraine compounds

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9233927

    Crystals of laquinimod sodium and improved process for the manufacture thereof

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9180097

    Formulations of 6-mercaptopurine

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9161935

    Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9161936

    Laquinimod for treatment of GABA mediated disorders

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9155775

    Process for manufacturing glatiramer acetate product

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9107832

    Risperidone microparticles formed by sublimation

    Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9066957

    Dry powder inhaler

    Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9063153

    Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

    Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9018170

    Reduced volume formulation of glatiramer acetate and methods of administration

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8975279

    Amine salts of laquinimod

    Expires Mon Mar 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8975442

    Process for the preparation of and crystalline forms of optical enantiomers of modafinil

    Expires Mon Mar 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8920373

    Reduced volume formulation of glatiramer acetate and methods of administration

    Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8889627

    Treatment of multiple sclerosis with combination of laquinimod and fingolimod

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8889661

    Treatment of lupus nephritis using laquinimod

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8815511

    Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate

    Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8809310

    Use of rasagiline for the treatment of multiple system atrophy

    Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8759302

    Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

    Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8729305

    Process for the preparation of and crystalline forms of optical enantiomers of modafinil

    Expires Mon May 15 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8709433

    Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate

    Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8691872

    Dispersions of rasagiline citrate

    Expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8673322

    Crystals of laquinimod sodium, and process for the manufacture thereof

    Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Teva Pharma have?

185 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Teva Pharma patents expire?

22 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.